The first day of clinical trials for Gleevec, Bud and Yvonne
Interviewee: Bud. Yvonne, Bud's wife, talks about the first day of the clinical trials in June of 1998. (DNAi Location: Applications > Genes and medicine > drug design > Bud's Story > The first patient)
Yvonne: Now this is the very first day â€“ fact is it's June of '98. I don't have the exact date, is when the clinical trials started and Bud was the first patient to take this and it was 25 milligrams. And there is a picture that was taken of him and Dr. Druker wishing him luck so we're pretty proud of that picture. And then this guy over here, he's showing you what the pill looks like so at that time it was a number but now it's known at Gleevecâ„¢. Bud: Yeah STI-571.
chronic myeloid leukemia,sti 571,brian druker,gleevec,location applications,dnai,romine,cml,interviewee,milligrams,yvonne,clinical trials,leukemia,bud,genes,medicine
- ID: 15042
- Source: DNALC.DNAi
CML causes an increased production of white blood cells. Bud and Yvonne talk about the breakthrough that brought Bud's white blood cell count back to normal.
Bud recounts receiving the diagnosis that he had chronic myeloid leukemia.
Brian Druker credits the drug company Novartis with recognizing the importance of Gleevec and accelerating the development and approval process.
Brian Druker talks about the drug he developed as a turning point in the war on cancer.
Brian Druker talks about Bud, the first patient restored to health by Gleevecâ¢.
Brian Druker talks about how Gleevec has restored patients' hope for the future.
Brian Druker reflects on the importance of understanding the causes of cancer for developing new treatments.
Brian Druker talks about how the drug he designed targets the molecular cause of CML.
15525. How Gleevec works to alleviate symptoms of myeloid leukemia, 3D animation with basic narration
View the animation to find out how the drug Gleevecâ¢ inhibits the molecular cause of chronic myeloid leukemia.
Brian Druker talks about sense of urgency.